Metagenomic Sequencing: New Tool for AMR Prediction in Bloodstream Infections
Accurate results produced by rapid metagenomics help initiate treatment 18–42 hours earlier than conventional tests
Metagenomic sequencing can provide rapid and actionable antimicrobial resistance predictions to treat bloodstream infections much faster than conventional laboratory tests and has the potential to save lives and better manage the use of antibiotics, according to new research presented at this year’s European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark.
The study led by Kumeren Govender, PhD, from the John Radcliffe Hospital, University of Oxford, UK, indicates that rapid metagenomics can provide accurate results within just six hours of knowing bacteria are growing in a blood sample.
“Antibiotic-resistant bloodstream infections are a leading killer in hospitals, and rapidly starting the right antibiotic saves lives,” says Govender. “Our results suggest that metagenomics is a powerful tool for the rapid and accurate diagnosis of pathogenic organisms and antimicrobial resistance, allowing for effective treatment 18 to 42 hours earlier than would be possible using standard culture techniques.”
Impact of metagenomics on antimicrobial-resistant bloodstream infections
Bloodstream infections can rapidly lead to sepsis, multiple organ failure, and even death. Early and appropriate antibiotic therapy is vital to control the infection. Antimicrobial resistance (AMR) is a major challenge when treating bloodstream infections, causing around 370,000 deaths and associated with nearly 1.5 million deaths in 2019.
The current method used in clinical settings to identify the pathogen causing the infection is long and laborious, requiring two time-consuming culture and sensitivity tests that take at least one to three days to complete. First, they involve isolating and identifying the pathogen and then, performing antimicrobial susceptibility testing to expose the bacteria to various antibiotics to see exactly which it will respond to—plus the best route and dose.
In contrast, clinical metagenomics sequences all the genetic material including infectious pathogens in a sample—all at once—so time spent running tests, waiting for results, and running more tests could be reduced.
Accuracy of AMR prediction: metagenomics vs. conventional tests
To find out more, researchers randomly selected 210 positive and 61 negative blood culture specimens for metagenomic sequencing from the Oxford University Hospital’s microbiology laboratory between December 2020 and October 2022.
DNA was sequenced and the resultant sequences were used to identify the species of pathogen causing infections—and also to spot common species that can contaminate blood cultures.
Sequencing was able to identify 99 percent of infecting pathogens including polymicrobial infections and contaminants, as well as giving negative results in 100 percent of culture-negative samples. In some instances, sequencing detected probable causes of infection missed by routine cultures, and in other instances identified uncultivable species where a result could not be determined.
Sequencing was also used to detect antibiotic resistance in the ten most common causes of infections. Researchers studied a total of 741 resistant and 4047 sensitive combinations of antibiotics and pathogens. Results of traditional culture-based testing and sequencing agreed 92 percent of the time. Similar performance could be obtained from raw reads after only two hours of sequencing and overall agreement was about 90 percent.
The average time from sample extraction to sequencing was four hours with complete AMR prediction done two hours later, producing actionable AMR results 18–42 hours before the conventional laboratory.
David Eyre, MBBS, PhD, professor of infectious diseases, University of Oxford, who co-led the study, commented, “This is a really exciting breakthrough that means we will be able to diagnose the cause of patients’ infections faster and more completely than has been possible before. We are working hard to continue to overcome some of the remaining barriers to metagenomic sequencing being used more widely, which include its current high cost, further improving accuracy, and creating improved laboratory expertise in these new technologies and simpler workflows for interpreting results.”
- This press release was supported by the European Society of Clinical Microbiology and Infectious Diseases